CompletedPhase 2NCT02299089

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Studying Acromegaly

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Camurus AB
Principal Investigator
Marianne Pavel, Professor
Charité Campus Virchow Klinikum, Berlin, Germany
Intervention
octreotide FluidCrystal® injection depot(drug)
Enrollment
12 enrolled
Eligibility
18 years · All sexes
Timeline
20152016

Study locations (10)

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02299089 on ClinicalTrials.gov

Other trials for Acromegaly

Additional recruiting or active studies for the same condition.

See all trials for Acromegaly

← Back to all trials